# Elikon Venture

> Elikon Venture is a VC fund backing Biotechnology, Medical and Pharmaceutical. See 12 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 12
- Last investment: Jul 2026
- Lead investor: 17%
- Last updated: Aug 2026

Elikon Venture is a venture capital firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 50% |
| Medical | 5 | 42% |
| Pharmaceutical | 4 | 33% |
| Health Care | 3 | 25% |
| Therapeutics | 3 | 25% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 33% |
| Series B | 3 | 25% |
| Seed | 2 | 17% |
| Series C | 2 | 17% |
| Venture - Series Unknown | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 5 | 42% |
| United States | 4 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CORE Biomedicine | CORE Biomedicine is a private, preclinical-stage biotechnology company that specializes in drug discovery and development for oncology. | $21M | Series A | Jul 28, 2026 |  |
| Oricell Therapeutics | OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy. | $110M | Venture - Series Unknown | Apr 09, 2026 |  |
| Fortitude Biomedicines | Fortitude Biomedicines is a biotechnology company that develops antibody-based biologic drugs targeting autoimmune diseases. | $13M | Seed | Jan 26, 2026 |  |
| Oricell Therapeutics | OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy. | $70M | Series C | Jan 12, 2026 |  |
| Angitia Biopharmaceuticals | Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. | $120M | Series C | Dec 11, 2024 |  |
| Angitia Biopharmaceuticals | Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. | $46M | Series B | Oct 19, 2023 |  |
| Innovac Therapeutics | Innovac Therapeutics operates as a biotechnology company dedicated to developing innovative vaccines for patients with unmet medical needs, using our proprietary RNA technology platforms and manufacturing capabilities. | $18M | Seed | Sep 01, 2023 |  |
| Eccogene | Eccogene is a Health Care Company. | $25.2M | Series B | Jun 12, 2023 |  |
| Allorion Therapeutics | Allorion Therapeutics is a small molecule therapeutic development company that focuses on cancer and autoimmune illnesses. Allorion operates two locations in Natick, Massachusetts, and Guangzhou, China. | $50M | Series B | Mar 09, 2023 |  |
| Ucello Therapeutics | Ucello Therapeutics is engaged in development of allogeneic cell therapies using its proprietary CAR-T cell technology platform CBT-X20. | $25M | Series A | Feb 10, 2022 |  |

10 of 12 investments shown.

## Co-investors
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 6 deals together
- [Lichen Capital](https://shizune.co/investors/profile/lichen-capital) — VC Fund, 4 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 4 deals together
- [Yonghua Capital](https://shizune.co/investors/profile/yongyong-investment) — VC Fund, 3 deals together
- [3H Health Investment](https://shizune.co/investors/profile/3h-health-investment) — VC Fund, 2 deals together
- [Beijing E-town International Investment & Development](https://shizune.co/investors/profile/beiid) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Elikon Venture invest in?

Elikon Venture invests primarily in Biotechnology, Medical and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 12 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Elikon Venture last invest?

The most recent investment recorded for Elikon Venture closed in Jul 2026. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co